Pharmacodynamic Approaches to Optimizing Beta-Lactam Therapy

被引：19

作者：

Crandon, Jared L. ^{[1
]}

Nicolau, David P. ^{[1
,2
]}

机构：

[1] Hartford Hosp, Ctr Antiinfect Res & Dev, Hartford, CT 06102 USA

[2] Hartford Hosp, Div Infect Dis, Hartford, CT 06102 USA

来源：

CRITICAL CARE CLINICS | 2011年 / 27卷 / 01期

关键词：

Beta-lactam; Pharmacodynamics; Prolonged infusion; Continuous infusion; PSEUDOMONAS-AERUGINOSA INFECTIONS; KLEBSIELLA-PNEUMONIAE PNEUMONIA; CRITICALLY-ILL PATIENTS; CONTINUOUS-INFUSION; PIPERACILLIN-TAZOBACTAM; CLINICAL PHARMACODYNAMICS; ANTIMICROBIAL TREATMENT; CONTINUOUS CEFTAZIDIME; INTERMITTENT INFUSION; TARGET ATTAINMENT;

D O I：

10.1016/j.ccc.2010.11.004

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Given their popularity and favorable safety profile, it is no wonder that there has been considerable interest in developing strategies to most effectively use beta-lactam therapy. Dating back to the first days of penicillin, it was noted that there was an observed benefit to prolonging the infusion time or dosing more frequently. Since that time, considerable research has been performed to help understand and justify these dosing strategies. This article discusses the pharmacology behind these dosing strategies and presents some of the contemporary literature describing the perceived and observed clinical benefits.

引用

页码：77 / +

页数：18

共 65 条

[1] Antimicrobial treatment guidelines for acute bacterial rhinosinusitis - Executive summary [J].

Anon, JB ;

Jacobs, MR ;

Roche, R ;

Poole, MD ;

Merck, D ;

Ambrose, PG ;

Benninger, MS ;

Hadley, JA ;

Craig, WA ;

Andes, DR ;

Bernstein, JM ;

Besser, RE ;

Dowell, SF ;

Drusano, GL ;

Klepser, ME ;

Nicolau, D ;

Radowsky, A ;

Reller, LB ;

Wald, ER ;

Zucker, DR .

OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2004, 130 (01) :1-45

[2] Guidelines for the management, of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia [J].

不详 .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (04) :388-416

[3]

[Anonymous], 1998, AM J MANAG CARE, V4, pS525

[4]

[Anonymous], SOC CRIT CAR MED 39

[5]

[Anonymous], RESP MED CME

[6] Assessment of an Alternative Meropenem Dosing Strategy Compared with Imipenem-Cilastatin or Traditional Meropenem Dosing After Cefepime Failure or Intolerance in Adults with Neutropenic Fever [J].

Arnold, Heather M. ;

McKinnon, Peggy S. ;

Augustin, Kristan M. ;

Hladnik, Lindsay M. ;

Casabar, Ed ;

Reichley, Richard M. ;

Dubberke, Erik R. ;

Westervelt, Peter ;

Ritchie, David J. .

PHARMACOTHERAPY, 2009, 29 (08) :914-923

[7] Use of pharmacokinetic-pharmaco dynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem [J].

Bhavnani, SM ;

Hammel, JP ;

Cirincione, BB ;

Wikler, MA ;

Ambrose, PG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) :3944-3947

[8] RANDOMIZED STUDY OF CARBENICILLIN PLUS CEFAMANDOLE OR TOBRAMYCIN IN THE TREATMENT OF FEBRILE EPISODES IN CANCER-PATIENTS [J].

BODEY, GP ;

KETCHEL, SJ ;

RODRIGUEZ, V .

AMERICAN JOURNAL OF MEDICINE, 1979, 67 (04) :608-616

[9] Comparison of Meropenem MICs and Susceptibilities for Carbapenemase-Producing Klebsiella pneumoniae Isolates by Various Testing Methods [J].

Bulik, Catharine C. ;

Fauntleroy, Kathy A. ;

Jenkins, Stephen G. ;

Abuali, Mayssa ;

LaBombardi, Vincent J. ;

Nicolau, David P. ;

Kuti, Joseph L. .

JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (07) :2402-2406

[10] Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study [J].

Chastre, Jean ;

Wunderink, Richard ;

Prokocimer, Philippe ;

Lee, Michael ;

Kaniga, Kone ;

Friedland, Ian .

CRITICAL CARE MEDICINE, 2008, 36 (04) :1089-1096

← 1 2 3 4 5 6 7 →